Safety of vaccines that have been kept outside of recommended temperatures: Reports to the Vaccine Adverse Event Reporting System (VAERS), 2008-2012
- PMID: 29248264
- DOI: 10.1016/j.vaccine.2017.11.083
Safety of vaccines that have been kept outside of recommended temperatures: Reports to the Vaccine Adverse Event Reporting System (VAERS), 2008-2012
Abstract
Background: Vaccines should be stored and handled according to manufacturer specifications. Inadequate cold chain management can affect potency; but, limited data exist on adverse events (AE) following administration of vaccines kept outside of recommended temperatures.
Objective: To describe reports to the Vaccine Adverse Event Reporting System (VAERS) involving vaccines inappropriately stored outside of recommended temperatures and/or exposed to temperatures outside of manufacturer specifications for inappropriate amounts of time.
Methods: We searched the VAERS database (analytic period 2008-2012) for reports describing vaccines kept outside of recommended temperatures. We analyzed reports by vaccine type, length outside of recommended temperature and type of temperature excursion, AE following receipt of potentially compromised vaccine, and reasons for cold chain breakdown.
Results: We identified 476 reports of vaccines kept outside of recommended temperatures; 77% described cluster incidents involving multiple patients. The most commonly reported vaccines were quadrivalent human papillomavirus (n = 146, 30%), 23-valent pneumococcal polysaccharide (n = 51, 11%), and measles, mumps, and rubella (n = 45, 9%). Length of time vaccines were kept outside of recommended temperatures ranged from 15 mins to 6 months (median 51 h). Most (n = 458, 96%) reports involved patients who were administered potentially compromised vaccines; AE were reported in 32 (7%), with local reactions (n = 21) most frequent. Two reports described multiple patients contracting diseases they were vaccinated against, indicating possible influenza vaccine failure. Lack of vigilance, inadequate training, and equipment failure were reasons cited for cold chain management breakdowns.
Conclusions: Our review does not indicate any substantial direct health risk from administration of vaccines kept outside of recommended temperatures. However, there are potential costs and risks, including vaccine wastage, possible decreased protection, and patient and parent inconvenience related to revaccination. Maintaining high vigilance, proper staff training, regular equipment maintenance, and having adequate auxiliary power are important components of comprehensive vaccine cold chain management.
Keywords: Medical errors; Temperature excursions; Vaccine Adverse Event Reporting System (VAERS); Vaccine safety; Vaccine storage and handling.
Published by Elsevier Ltd.
Similar articles
-
Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990-2013.Vaccine. 2016 May 27;34(25):2841-6. doi: 10.1016/j.vaccine.2016.04.021. Epub 2016 Apr 15. Vaccine. 2016. PMID: 27087150 Free PMC article.
-
Vaccination errors reported to the Vaccine Adverse Event Reporting System, (VAERS) United States, 2000-2013.Vaccine. 2015 Jun 22;33(28):3171-8. doi: 10.1016/j.vaccine.2015.05.006. Epub 2015 May 14. Vaccine. 2015. PMID: 25980429
-
Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990--2003.Vaccine. 2008 Feb 26;26(9):1166-72. doi: 10.1016/j.vaccine.2007.12.049. Epub 2008 Jan 22. Vaccine. 2008. PMID: 18255204 Review.
-
Understanding vaccine safety information from the Vaccine Adverse Event Reporting System.Pediatr Infect Dis J. 2004 Apr;23(4):287-94. doi: 10.1097/00006454-200404000-00002. Pediatr Infect Dis J. 2004. PMID: 15071280 Review.
-
Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.MMWR Surveill Summ. 2003 Jan 24;52(1):1-24. MMWR Surveill Summ. 2003. PMID: 12825543
Cited by
-
Designed nanoparticles elicit cross-reactive antibody responses to conserved influenza virus hemagglutinin stem epitopes.PLoS Pathog. 2023 Aug 28;19(8):e1011514. doi: 10.1371/journal.ppat.1011514. eCollection 2023 Aug. PLoS Pathog. 2023. PMID: 37639457 Free PMC article.
-
Vaccination process evaluation at COVID-19 vaccination centers in Lebanon: a national study.J Pharm Policy Pract. 2022 Oct 15;15(1):63. doi: 10.1186/s40545-022-00459-3. J Pharm Policy Pract. 2022. PMID: 36243870 Free PMC article.
-
Development of Dog Vaccination Strategies to Maintain Herd Immunity against Rabies.Viruses. 2022 Apr 16;14(4):830. doi: 10.3390/v14040830. Viruses. 2022. PMID: 35458560 Free PMC article.
-
Adherence to WHO vaccine storage codes and vaccine cold chain management practices at primary healthcare facilities in Dalocha District of Silt'e Zone, Ethiopia.Trop Dis Travel Med Vaccines. 2022 Apr 20;8(1):10. doi: 10.1186/s40794-022-00167-5. Trop Dis Travel Med Vaccines. 2022. PMID: 35440066 Free PMC article.
-
Stability Modelling of mRNA Vaccine Quality Based on Temperature Monitoring throughout the Distribution Chain.Pharmaceutics. 2022 Feb 17;14(2):430. doi: 10.3390/pharmaceutics14020430. Pharmaceutics. 2022. PMID: 35214162 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical